Biocon Biologics Symposium on #100 Years of Insulin Delivering on Universal Access Equitable Care# Resonates Well With Leading KOLs at IDF Congress 2019

Food and Healthcare Press Releases Thursday December 12, 2019 10:27
BENGALURU, India--12 Dec--PRNewswire/InfoQuest

Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, brought together Key Opinion Leaders (KOLs), including physicians, scientists, healthcare professionals, government representatives, policy makers, and IDF members, at its symposium on '100 years of Insulin – Delivering on Universal Access & Equitable Care' held during the IDF Congress 2019, at Busan, South Korea. The symposium was held as an extension of its Universal Access Program aimed at getting diverse stakeholders to join its mission of Unlocking access to insulins through its 10 cents mission.

The Symposium was opened by Mr Satish Sivan, the Deputy Chief of Mission, Embassy of India in Korea, who appreciated the efforts being made by Biocon Biologics to unlock affordable access to insulins for patients across the globe. "India has been rightly called the pharmacy capital of the world with consistent track record in producing high quality affordable pharmaceutical products with advances in Biological therapeutics. India has seen companies like Biocon become world leaders in developing Biosimilars therapeutics entities especially for diabetes and cancer," he said.

The Symposium was addressed by   Dr Andrew Boulton, Professor at Manchester University and President, IDF, Dr Radhakrisha Sothiratnam, consultant physician, Columbia Asia Hospital, Seremban, Malaysia, Dr Irl Hirsch, Professor of Metabolism, Endocrinology and Nutrition, University of Washington, U.S., Renza Scibilia, Manager- Type 1 Diabetes and consumer Voice, Diabetes Australia.

"Is diabetes the cancer of 21st century? Neither malaria nor AIDS, but diabetes is the biggest health challenge today. Explosion of Diabetes in Asia is resulting in a rising Global Public Tsunami. A 150% rise in type 2 diabetes in South Asia from 2000 to 2035, has been estimated. Lack of equitable access to affordable insulin remains a key impediment to successful treatment and results in co-morbid complications and premature deaths. In developed markets too, people outside the health security net find it difficult to afford expensive insulins therapy. To tackle this huge economic burden that diabetes poses, governments across the world need to ensure that they have a universal health coverage system, which includes insulin and diabetes care," said Dr Andrew Boulton, Professor at Manchester University and President, IDF.

"Our symposium at IDF Congress brought together leading KOLs from across the globe to seek viable, long-term solutions to improve insulin access and affordability. The discussions pointed towards diabetes being a universal challenge for patients not just in LMICs but also in developed markets like the US, where patients outside the health security net are forced to ration insulins due to its high cost.   We believe Biocon Biologics along with other stakeholders including like-minded insulins providers can enable equitable access to insulins for patients globally," said Christiane Hamacher, CEO, Biocon Biologics.

Read More: http://bit.ly/PR191211
Logo: https://mma.prnewswire.com/media/1039641/Biocon_Biocologics_Logo.jpg

Latest Press Release

COVID-19 Handbook from the Jack Ma Foundation and Alibaba Foundation Now in Thai

The COVID-19 Prevention and Treatment Handbook supported by the Jack Ma Foundation and Alibaba Foundation is now available in Thai. Written by doctors from First Affiliated Hospital, Zhejiang University School of Medicine who were on the frontline of...

Bosch Developing COVID-19-(SARS-CoV-2) Rapid Testing Kit for the Vivalytic Platform

- One of the world's first multiplex molecular diagnostic tests that can identify COVID-19 and distinguish it from nine other respiratory infections with similar symptoms, like influenza - The test meets the requirements of the World Health Organization...

Designer and Manufacturer ASTOUND Group Develops and Builds Innovative Designs for Rapid Response COVID-19 Containment Kiosks in 72 Hours

ASTOUND Group, designer and manufacturer of exhibits, events and experiences has converted its production facilities in Las Vegas, Portland, Milwaukee and Toronto to manufacture and deploy medical grade COVID-19 containment check-in units for hospitals...

Living Younger and Happier in the Aging Society with Taiwan Excellence Award Winning Products

The advantages of Taiwan's medical and healthcare industry have been strongly demonstrated with the outbreak of COVID-19. Other than developing counter-measures against this current epidemic, “Aging Society”, a hidden crisis around the world....

ASTM International Provides Public Access to Standards Used For COVID-19

Global standards organization ASTM International is providing no-cost public access to a suite of two dozen important standards used in the production and testing of personal protective equipment to combat the COVID-19 (coronavirus) public health...

Related Topics